Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement